Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 8Hodgkin Disease 3Sarcoma 2Neoplasm Metastasis 2Thyroid Neoplasms 1Solitary Fibrous Tumors 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Osteosarcoma 1Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Hemangioendothelioma 1Chondrosarcoma, Extraskeletal Myxoid 1Chondrosarcoma 1Carcinoma, Medullary 1Bone Neoplasms 1

Interventions

vandetanib 3selpercatinib 2rovalpituzumab tesirine 1pralsetinib 1Peripheral Blood Stem Cell Transplantation 1Indium 1Imatinib Mesylate 1Filgrastim 1Doxorubicin 1Dexamethasone 1Dacarbazine 1Capecitabine 1Calcium Aluminosilicate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Medullary × Dacarbazine × Clear all
NCT00354523 2014-12-17

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
21 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡